Sputnik-V, the world’s first registered vaccine against coronavirus, has demonstrated considerable efficacy in studies.
new Delhi . The trial of the coronavirus vaccine is now in the final stages. Scientists from all countries are making different claims about their vaccines. Meanwhile Russia has said that according to interim test results, its Sputnik-V vaccine is 92 percent effective in protecting people from corona. Russia’s National Research Center for Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF) announced this on Wednesday and reported that Sputnik-V, the world’s first registered vaccine against coronavirus, performed quite effectively in the study.
Currently Phase III (Phase-3) clinical trials of Sputnik V have been approved and are underway in Phase II and III in Belarus, UAE, Venezuela and other countries as well as India. A separate detailed study is also being conducted regarding the safety and effects of the vaccine for elderly people.
This confirmation is based on the first interim data of 40,000 volunteers from one of the largest double-blind, randomized, placebo-controlled phase-3 clinical trials in Russia. The vaccine dose was given in a trial conducted on a total of 16 thousand volunteers.
As a result of a statistical analysis of 20 confirmed cases of coronavirus, the case between the vaccinated individuals and those receiving the placebo separately indicates that the effect rate remained 92 percent after the second dose of Sputnik V vaccine.
The vaccine was given to a group of volunteers from the Red Zone of Russian hospitals for the first time in September. Even after the vaccination of 10,000 people involved, its efficacy rate has been confirmed to be more than 90 percent.
The data obtained will be published by researchers from the Gamalaya Center in one of the world’s premier peer reviewed medical academic journals, with independent evaluation of the data by leading epidemiological experts.
As of November 11, more than 20,000 volunteers have been given the first dose of the vaccine and the first and second doses to more than 16,000 volunteers as part of ongoing clinical trials at 29 medical centers across Russia.
In addition, no unexpected adverse events have been identified in the research until November 11, which is a good indication. Some of the people who were given the vaccine have received minor complaints, such as pain at the injection site, flu-like syndrome, which includes fever, weakness, fatigue and headaches.
The safety of the vaccine is constantly being monitored during clinical trials. The information is analyzed by an independent monitoring committee, consisting of prominent Russian scientists. The observation of study participants will continue for six months, after which the final report will be presented. Research data will be provided by RDIF to national regulators of countries willing to purchase the Russian vaccine to streamline the registration process. Russian Federation Health Minister Mikhail Murashko said that the use of the vaccine and the results of clinical trials show that it is an efficient solution to prevent coronavirus infection and is the most successful way to defeat the epidemic.